e financial performance, as well as other statements
containing the words "believes," "anticipates," "plans," "expects," "will"
and similar expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995. Actual
results may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including Cynosure's
history of operating losses, its reliance on sole source suppliers, the
inability to accurately predict the timing or outcome of regulatory
decisions, changes in consumer preferences, competition in the aesthetic
laser industry, economic, market, technological and other factors discussed
in Cynosure's most recent Annual Report on Form 10-K, which is filed with
the Securities and Exchange Commission. In addition, the forward-looking
statements included in this press release represent Cynosure's views as of
the date of this press release. Cynosure anticipates that subsequent events
and developments will cause its views to change. However, while Cynosure
may elect to update these forward- looking statements at some point in the
future, it specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as representing
Cynosure's views as of any date subsequent to the date of this press
release.
Consolidated Statements of Income
(In thousands, except per share data)
Three Months Ended March 31,
2008 2007
(unaudited)
Revenues $36,763 $26,077
Cost of revenues 12,371 9,922
Gross profit 24,392 16,155
Operating expenses
Selling and marketing
'/>"/>
SOURCE Cynosure, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 Related biology technology :1.
Cynosure to Present at the Leerink Swann & Company/MEDACorp Aesthetics Roundtable Conference2.
Cynosure to Announce Fourth-Quarter and Full Year 2007 Financial Results on February 123.
Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 20074.
Cynosure Announces Upcoming Investor Presentations at Cowen and Citi Investor Conferences5.
Cynosure Introduces Smartlipo MPX(TM) Dual Wavelength Workstation for LaserBodySculpting(SM)6.
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound7.
QMed, Inc. Reports July Medicare SNP Enrollments8.
Phlo Affiliate Reports Expanded Coverage to Oregon Border9.
Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results10.
Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 200711.
Carrington Reports Second Quarter 2007 Results